



8th WBMT SYMPOSIUM

PROGRAM

February 27, 2022 | Virtual/Hybrid



AFBMT / NIBMT
Rawalpindi - Pakistan

WORLDWIDE NETWORK FOR BLOOD AND MARROW TRANSPLANTATION

www.WBMT.org | www.WBMT2022Pakistan.com

Session-I	Transplant Strategies in 2022			February 27, 2022
Session Time	0830-1030 hrs (PST/GMT+5)	Chair(s)	Parvez Ahmed, Pakistan	
0830-0850 hrs	Bone marrow versus peripheral blood as stem cell source Raheel Iftikhar, Pakistan			
0850-0910 hrs	Current indications and conditioning regimens for Haploidentical HSCT Qaisar Bashir, USA			
0910-0930 hrs	Optimal GVHD prophylaxis in HSCT Shahrukh K. Hashmi, UAE			
0930-0950 hrs	Improving transplant outcomes with reduced intensity conditioning regimens Mohamad Mohty, France			
0950-1030 hrs	Panel Discussion			
1030-1045 hrs	Coffee Break			
Session-II	Complications of HSCT			
Session Time	1045-1230 hrs (PST/GMT+5)	Chair(s)	Salman Naseem Adil, Pakistan	
1045-1105 hrs	Management of steroid refractory acute and chronic GVHD Hildegard Greinix, Austria			
1105-1125 hrs	Managing relapse / graft failure post HSCT Salman Fazal, USA			
1125-1145 hrs	Management of infectious complications post HSCT Sebastian Galeano, Uruguay			
1145-1230 hrs	Panel Discussion			
1230-1330 hrs	Lunch Break			
Session-III	HSCT in non-malignant diseases			
Session Time	1330-1430 hrs (PST/GMT+5)	Chair(s)	Qamar Un Nisa Chaudhry, Pakistan	
1330-1345 hrs	HSCT in bone marrow failure syndromes Damiano Rondelli, USA			
1345-1400 hrs	HSCT in thalassemia/SCD Tariq Ghafoor, Pakistan			
1400-1415 hrs	HSCT in Immunodeficiency Disorders Carmem Bonfim, Brazil			
1415-1445 hrs	Panel Discussion			
1445-1500 hrs	Coffee Break			
Session-IV	HSCT in hematological malignancies			
Session Time	1500-1700 hrs (PST/GMT+5)	Chair(s)	Parvez Ahmed, Pakistan	
1500-1520 hrs	HSCT in myelodysplastic syndrome and acute myeloid leukemia Dietger Niederwieser, Germany			
1520-1540 hrs	HSCT in acute lymphoblastic leukemia Munira Moosajee, Pakistan			
1540-1600 hrs	Current Indications of HSCT in non-hodgkin lymphoma Farrukh T. Awan, USA			
1600-1620 hrs	HSCT for multiple myeloma in the era of novel drugs Saad Z. Usmani, USA			
1620-1640 hrs	Current place of CAR-T cell therapy in managing hematological malignancies Mickey Koh, UK/Singapore			
1640-1715 hrs	Panel Discussion			
1715-1720 hrs	Closing Remarks		Parvez Ahmed, Pakistan	